Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03804424 · ClinicalTrials.gov registry record · Early Phase 1
64Cu-LLP2A for Imaging Multiple Myeloma
A Early Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT03804424: Clinical Trial Early Phase 1 study, sponsored by Washington University School of Medicine.
NCT03804424 is a Early Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 10 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03804424, a Early Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The investigators are performing a trial with goals to demonstrate the feasibility of imaging multiple myeloma (MM) patients with 64Cu-LLP2A-positron emission tomography (PET)/magnetic resonance (MR). The investigators suggest that 64Cu-LLP2A will allow for an accurate molecular imaging of MM lesions, which will have an important impact on early stage disease detection and in the long term on the initiation and choice of therapy in these patients.
Primary Outcome
-Average organ activity concentration will be measured and decay corrected by utilizing regions of interest (ROIs) drawn around all organs visible on 64Cu-LLP2A images. Activity organ residence times will be calculated by numerical or analytical integration of the time-activity curves. Uptake/clearance functional fits of mono or bi-exponential functions will be performed and analytical integration, accounted for physical delay, will be performed. The calculated residence times will be used with
Interventions
- DEVICE PET/MR
- DRUG 64Cu-LLP2A
- PROCEDURE Urine sample
- PROCEDURE Blood samples for serum stability
- PROCEDURE Blood samples for metabolite analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-11-20 |
| Est. Completion | 2021-10-01 |
| Phase | Early Phase 1 |
Why NCT03804424 stopped before completion
NCT03804424 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 5 interventions - of which PET/MR is the first listed.
NCT03804424 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03804424 about?
NCT03804424 is a clinical study titled "64Cu-LLP2A for Imaging Multiple Myeloma". The investigators are performing a trial with goals to demonstrate the feasibility of imaging multiple myeloma (MM) patients with 64Cu-LLP2A-positron emission tomography (PET)/magnetic resonance (MR). The investigators suggest that 64Cu-LLP2A will allow for an accurate molecular imaging of MM lesion...
What is the current status of trial NCT03804424?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2018-11-20. Estimated completion is 2021-10-01.
What interventions are being tested in trial NCT03804424?
The interventions under investigation include: PET/MR (DEVICE), 64Cu-LLP2A (DRUG), Urine sample (PROCEDURE), Blood samples for serum stability (PROCEDURE), Blood samples for metabolite analysis (PROCEDURE).
Who is sponsoring clinical trial NCT03804424?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03804424's enrollment target sits among peer trials
10 1628th of 2000 higher than 256 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI